Intravenous Ketamine for Adolescents with Treatment-Resistant Depression: An Open-Label Study
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Novel interventions for treatment-resistant depression (TRD) in adolescents are urgently needed. Ketamine has been studied in adults with TRD, but little information is available for adolescents. This study investigated efficacy and tolerability of intravenous ketamine in adolescents with TRD, and explored clinical response predictors. METHODS: Adolescents, 12-18 years of age, with TRD (failure to respond to two previous antidepressant trials) were administered six ketamine (0.5 mg/kg) infusions over 2 weeks. Clinical response was defined as a 50% decrease in Children's Depression Rating Scale-Revised (CDRS-R); remission was CDRS-R score ≤28. Tolerability assessment included monitoring vital signs and dissociative symptoms using the Clinician-Administered Dissociative States Scale (CADSS). RESULTS: Thirteen participants (mean age 16.9 years, range 14.5-18.8 years, eight biologically male) completed the protocol. Average decrease in CDRS-R was 42.5% (p = 0.0004). Five (38%) adolescents met criteria for clinical response. Three responders showed sustained remission at 6-week follow-up; relapse occurred within 2 weeks for the other two responders. Ketamine infusions were generally well tolerated; dissociative symptoms and hemodynamic symptoms were transient. Higher dose was a significant predictor of treatment response. CONCLUSIONS: These results demonstrate the potential role for ketamine in treating adolescents with TRD. Limitations include the open-label design and small sample; future research addressing these issues are needed to confirm these results. Additionally, evidence suggested a dose-response relationship; future studies are needed to optimize dose. Finally, questions remain regarding the long-term safety of ketamine as a depression treatment; more information is needed before broader clinical use.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643 · cited 1×
“Research in adult depression has taught us that the more serial treatments are required, the lower the likelihood of achieving remission (Rush et al. 2006).”
Brain development during childhood and adolescence: a longitudinal MRI study
Giedd, J. N., Blumenthal, J., Jeffries, N. O., Castellanos, F. X., Liu, H., Zijdenbos, A., Paus, T., Evans, A. C., & Rapoport, J. L. (1999) · Nature Neuroscience · doi:10.1038/13158 · Cited by 5,552
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
Why do many psychiatric disorders emerge during adolescence?
Paus, T., Keshavan, M., & Giedd, J. N. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2513 · Cited by 3,123 · cited 1×
“Since adolescence is a time period notable both for onset of depression and ongoing neurodevelopment (Giedd et al. 1999; Paus et al. 2008; Raznahan et al. 2011) it represents a critical window to intervene and restore healthy developmental trajectories.”
A scale for the assessment of hedonic tone the Snaith-Hamilton pleasure scale
Snaith, R. P., Hamilton, M., Morley, S., Humayan, A., Hargreaves, D., & Trigwell, P. (1995) · British Journal of Psychiatry · doi:10.1192/bjp.167.1.99 · Cited by 1,778
Wechsler Abbreviated Scale of Intelligence--Second Edition
Wechsler, D. (2018) · PsycTESTS Dataset · doi:10.1037/t15171-000 · Cited by 1,153
Bremner, J. D., Krystal, J. H., Putnam, F. W., Southwick, S. M., Marmar, C., Charney, D. S., & Mazure, C. M. (1998) · Journal of Traumatic Stress · doi:10.1023/a:1024465317902 · Cited by 817 · cited 5×
“CADSS scores were elevated immediately after each infusion (stronger effects for earlier infusions) but returned to baseline by the 1-hour assessment (Fig.”
InfluentialMurrough, J. W., Perez, A. M., Pillemer, S., Stern, J., Parides, M. K., aan het Rot, M., Collins, K. A., Mathew, S. J., Charney, D. S., & Iosifescu, D. V. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.06.022 · Cited by 786
Raznahan, A., Shaw, P., Lalonde, F., Stockman, M., Wallace, G. L., Greenstein, D., Clasen, L., Gogtay, N., & Giedd, J. N. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.0054-11.2011 · Cited by 712
Safety and Efficacy of Repeated-Dose Intravenous Ketamine for Treatment-Resistant Depression
aan het Rot, M., Collins, K. A., Murrough, J. W., Perez, A. M., Reich, D. L., Charney, D. S., & Mathew, S. J. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.08.038 · Cited by 690
Ketamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression.
Newport, D. J., Carpenter, L. L., McDonald, W. M., Potash, J. B., Tohen, M., Nemeroff, C. B., & The APA Council of Research Task Force on Novel Biomarkers and Treatments (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15040465 · Cited by 598 · cited 1×
“%) met criteria for clinical response and remission, with three of these responders showing sustained remission at The rate of response to ketamine in this adolescent study was lower than what has been observed in adult TRD studies (Fond et al. 2014; Newport et al. 2015; Xu et al. 2016).”
Scofield, M. D., Heinsbroek, J. A., Gipson, C. D., Kupchik, Y. M., Spencer, S., Smith, A. C. W., Roberts-Wolfe, D., & Kalivas, P. W. (2016) · Pharmacological Reviews · doi:10.1124/pr.116.012484 · Cited by 598
Cerebral plasticity: windows of opportunity in the developing brain
Ismail, F. Y., Fatemi, A., & Johnston, M. V. (2017) · European Journal of Paediatric Neurology · doi:10.1016/j.ejpn.2016.07.007 · Cited by 572
Side-effects associated with ketamine use in depression: a systematic review
Short, B., Fong, J., Galvez, V., Shelker, W., & Loo, C. K. (2018) · The Lancet Psychiatry · doi:10.1016/s2215-0366(17)30272-9 · Cited by 558
Ketamine administration in depressive disorders: a systematic review and meta-analysis
Fond, G., Loundou, A., Rabu, C., Macgregor, A., Lançon, C., Brittner, M., Micoulaud-Franchi, J.-A., Richieri, R., Courtet, P., Abbar, M., et al. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3664-5 · Cited by 339 · cited 2×
“%) met criteria for clinical response and remission, with three of these responders showing sustained remission at The rate of response to ketamine in this adolescent study was lower than what has been observed in adult TRD studies (Fond et al. 2014; Newport et al. 2015; Xu et al. 2016).”
From Serotonin to Neuroplasticity: Evolvement of Theories for Major Depressive Disorder
Liu, B., Liu, J., Wang, M., Zhang, Y., & Li, L. (2017) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2017.00305 · Cited by 249 · cited 2×
“Novel interventions are urgently needed to address adolescent TRD. Ketamine’s biological effects may serve to enhance neuro-plasticity (Liu et al. 2017).”
Ketamine Safety and Tolerability in Clinical Trials for Treatment-Resistant Depression
Wan, L.-B., Levitch, C. F., Perez, A. M., Brallier, J. W., Iosifescu, D. V., Chang, L. C., Foulkes, A., Mathew, S. J., Charney, D. S., & Murrough, J. W. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13m08852 · Cited by 231 · cited 2×
“The average response rate in published studies testing ketamine for adult TRD is 67% (Wan et al. 2015), which is considerably higher than TRD interventions (e.g., the average response rate for transcranial magnetic stimulation is 45% (Conelea et al. 2017).”
Xu, Y., Hackett, M., Carter, G., Loo, C., Gálvez, V., Glozier, N., Glue, P., Lapidus, K., McGirr, A., Somogyi, A. A., et al. (2016) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv124 · Cited by 226 · cited 2×
“4 mg/kg) (Xu et al. 2016) and that dose escalation from 0.”
The Treatment for Adolescents With Depression Study (TADS)
MARCH, J., SILVA, S., & VITIELLO, B. (2006) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000237709.35637.c0 · Cited by 174 · cited 1×
“Unfortunately, about 40% of adolescents do not respond to their first intervention (March et al. 2006), and only half of nonresponders respond to the second treatment (Brent et al. 2008).”
Psychiatric safety of ketamine in psychopharmacology research
Perry, E. B., Cramer, J. A., Cho, H.-S., Petrakis, I. L., Karper, L. P., Genovese, A., O’Donnell, E., Krystal, J. H., D’Souza, D. C., & Yale Ketamine Study Group (2007) · Psychopharmacology · doi:10.1007/s00213-007-0706-2 · Cited by 117
Risks Associated with Misuse of Ketamine as a Rapid-Acting Antidepressant
Zhu, W., Ding, Z., Zhang, Y., Shi, J., Hashimoto, K., & Lu, L. (2016) · Neuroscience Bulletin · doi:10.1007/s12264-016-0081-2 · Cited by 80
Moretti, R. J., Hassan, S. Z., Goodman, L. I., & Meltzer, H. Y. (1984) · Anesthesia & Analgesia · doi:10.1213/00000539-198412000-00007 · Cited by 51
Cited by
Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms
Inserra, A., De Gregorio, D., & Gobbi, G. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000056 · Cited by 232
Lan, X., Wang, C., Zhang, F., Liu, H., Li, W., Ye, Y., Hu, Z., Mai, S., Ning, Y., & Zhou, Y. (2023) · Child and Adolescent Psychiatry and Mental Health · doi:10.1186/s13034-023-00647-2 · Cited by 22
“Two small open-label trials, one including 13 adolescent TRD and the other including 12 adolescents with treatment-refractory bipolar depression also suggested that ketamine was an effective and safe treatment for this adolescent population [9, 10].”
BackgroundNew Somatic Treatments for Child and Adolescent Depression
Cullen, K. R., Padilla, L. E., Papke, V. N., & Klimes-Dougan, B. (2019) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-019-00194-8 · Cited by 5
Self-citationSedation in the Emergency Department: A Complex and Multifactorial Challenge
Kennedy, R. M. (2021) · Pediatric Sedation Outside of the Operating Room · doi:10.1007/978-3-030-58406-1_22 · Cited by 1
Metadata
- Authors
- Cullen, K. R., Amatya, P., Roback, M. G., Albott, C. S., Westlund Schreiner, M., Ren, Y., Eberly, L. E., Carstedt, P., Samikoglu, A., Gunlicks-Stoessel, M., Reigstad, K., Horek, N., Tye, S., Lim, K. O., & Klimes-Dougan, B.
- Venue
- Journal of Child and Adolescent Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2018-09
- Volume
- 28
- Issue
- 7
- Pages
- 437-444
- ISSN
- 1044-5463 (ISSN-L)
- 1557-8992
- OpenAlex
- W2884469025
- Cited by
- 117
- References
- 22
- FWCI
- 3.92
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.